Biomarker may 'revolutionise' colorectal cancer management

In one study, not a single patient with a negative marker relapsed

Personalised circulating tumour DNA could have the potential to be the biomarker routinely used by oncologists treating patients with colorectal cancer, two new studies suggest.

phlebologist holding a tube of blood

The “exciting technology” may eventually be used to predict who will have recurrence after surgery; who should have adjuvant chemotherapy; and in assessing whether therapy has worked, say the authors of an editorial in JAMA Oncology discussing both pieces of research.

Both studies followed patients with stage I-III